Poland· PL-100507850
Otrivin ipra MAX
A xylometazoline product containing xylometazolini hydrochloridum + ipratropii bromidum, registered in Poland by InPharm Sp. z o.o.. The same ATC class is registered in 10 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Xylometazoline is registered in 10 of 19 countries.
Countries holding a registration under ATC R01AB06 (xylometazoline), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Xylometazoline · ATC R01AB06
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Xylometazolini hydrochloridum + Ipratropii bromidum
- Manufacturer
- InPharm Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- R01AB06
- ATC class
- Xylometazoline
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05909991558598
- gtin05909991558604
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
63 interactions on record for xylometazoline.
Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Xylometazoline · interactions on record
63 records
- 6 severe
- 54 moderate
Most severe, free to view
- MethylergometrineG02AB01severe
- DihydroergotamineN02CA01severe
- ErgotamineN02CA02severe
- MethysergideN02CA04severe
3 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Xylometazoline in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaOTRIVIN DUOHaleon Czech Republic s.r.o., Praha
- SwedenOtrivin Comp 0,5 mg/ml + 0,6 mg/ml Nässpray, lösningHaleon Denmark ApS
- FinlandOtrivin CompHaleon Denmark ApS
- NorwayOtrivin CompHaleon Denmark ApS
- IcelandOtrivin CompHaleon Denmark ApS
- NetherlandsOtrivin Duo Xylometazolinehydrochloride & Ipratropiumbromide, 0,5/0,6 mg/ml, neusspray, oplossingHaleon Netherlands B.V.
- SpainRHINOVIN DUO 0,5 mg/ml + 0.6 mg/ml SOLUCION PARA PULVERIZACION NASALHaleon Spain S.A.
- United KingdomOtrivine Extra Dual Relief 0.5mg/ml / 0.6mg/ml nasal sprayHaleon UK Trading Ltd
Authorised across Europe · EMA
The same active substance is authorised in 26 EEA countries. Names it is sold under:
- Austria · Otrivin Duo
- Belgium · Otrivine Duo
- Cyprus · Otrivin Advance
- Czechia · Otrivin Duo
- Denmark · Otrivin Comp, Zymelin Plus
- Estonia · Otrivin Total
- Spain · Rhinovin Duo
- Finland · Otrivin Comp
- United Kingdom (Northern Ireland) · Otrivine Extra Dual Relief
- Greece · Otrivin Advance
- Croatia · Ksilometazolinklorid/Ipratropijev Bromid Acino, Nasoryl
- Hungary · Otrivin Komplex
- Ireland · Otrivine Extra Dual Relief
- Iceland · Otrivin Comp
- Italy · Rinazina Doppia Azione
- Lithuania · Otriduo
- Luxembourg · Otrivine Duo
- Latvia · Otrivin Total
- Malta · Otrivine Extra Dual Relief
- Netherlands · Otrivin Duo
- Norway · Otrivin Comp, Zycomb
- Portugal · Nasitrim Duoeffect, Vibrocil Actilongduo
- Romania · Rhinxyl Plus, Vibrocil Duo
- Sweden · Otrivin Comp, Zymelin Comp
- Slovenia · Maresyl Comb, Otrivin Duo
- Slovakia · Otrivin Duo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/af14d074-7506-4b67-9bf5-27085b1139d9 GET /v1/drugs/af14d074-7506-4b67-9bf5-27085b1139d9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Aerozol do nosa, roztwór",
"source": "urpl",
"strength": "(0,5 mg + 0,6 mg)/ml",
"packaging": "05909991558598 ¦ OTC ¦ 158802\n1 butelka 10 ml\n05909991558604 ¦ OTC ¦ 158804\n1 butelka 10 ml",
"substance": null,
"common_name": "Xylometazolini hydrochloridum + Ipratropii bromidum",
"pl_product_id": "100507850",
"pozwolenie_nr": "384/24",
"auth_procedure": "IR",
"authorisation_validity": "2029-11-05"
}See everything about xylometazoline.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.